MedTrace Logo

Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy

NCT02945163 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2020-02-18

No results posted yet for this study

Summary

Tenofovir+lamivudine+efavirenz is still the first line regimen of combination antiretroviral therapy in developing countries. Based on our previous data, we aim to evaluate whether reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects while not scarifying their virological efficacy.

Conditions

  • HIV Infections

Interventions

DRUG

Tenofovir

Tenofovir Disoproxil Fumarate

DRUG

Lamivudine

Lamivudine

DRUG

Efavirenz

Efavirenz

Sponsors & Collaborators

  • The Second Hospital of Nanjing Medical University

    collaborator OTHER

  • Yunnan Provincial Infectious Disease Hospital

    collaborator OTHER

  • Shanghai Public Health Clinical Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-05
Primary Completion
2019-06-05
Completion
2019-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02945163 on ClinicalTrials.gov